Is Timing Everything?

被引：0

作者：

Rizzieri, David ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27710 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2014年 / 20卷 / 02期

关键词：

ACUTE MYELOID-LEUKEMIA; TRANSPLANTATION;

D O I：

10.1016/j.bbmt.2013.12.556

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：145 / 146

页数：2

共 6 条

[1] No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission [J].

Cahn, JY ;

Labopin, M ;

Sierra, J ;

Blaise, D ;

Reiffers, J ;

Ferrant, A ;

Bergmann, L ;

Visani, G ;

Cornelissen, J ;

De Witte, T ;

Bosi, A ;

Frassoni, F ;

Gorin, NC .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (02) :308-314

[2] Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) [J].

Estey, Elihu ;

de Lima, Marcos ;

Tibes, Raoul ;

Pierce, Sherry ;

Kantarjian, Hagop ;

Champlin, Richard ;

Giralt, Sergio .

BLOOD, 2007, 109 (04) :1395-1400

[3] Survival for older patients with acute myeloid leukemia: a population-based study [J].

Oran, Betul ;

Weisdorf, Daniel J. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1916-1924

[4]

Pasquini M., 2011, Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2011

[5]

Tallman MS, 2000, BLOOD, V96, P1254

[6]

Warlick E, 2013, BIOL BLOOD MARROW TR, V20, P198

← 1 →